3D |
three dimensional |
ACDA |
acid citrate dextrose solution |
ADSC |
Adipose-derived mesenchymal stem cells |
Ang 1 |
angiopoietin-1 |
BCT |
blood cell therapy |
βIgH3 |
factor-β-induced protein Ig-H3 |
CE |
European conformity |
CEO |
chief executive officer |
EC |
endothelial cells |
FBA |
fibrin bead assay |
FBS |
fetal bovine serum |
GMP |
good manufacturing practices |
HA |
hyaluronic acid |
HGF |
hepatocyte growth factor |
HUVEC |
human umbilical vein endothelial cells |
IGFBP7 |
insulin-like growth factor binding protein 7 |
LP-PRP |
leukocyte poor PRP |
LR-PRP |
leukocyte rich PRP |
NHDF |
normal human dermal fibroblasts |
MDD |
medical device directive |
MDR |
medical device regulation |
MDSAP |
medical device single audit program |
MNC |
mononuclear cells |
MTT |
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide |
OA |
osteoarthritis |
Ph. Eur |
European pharmacopeia |
PPP |
platelet poor plasma |
PRP |
platelet-rich plasma |
PRP-HA |
platelet-rich plasma combined with hyaluronic acid |
PL |
platelet lysates |
SMA |
smooth muscle actin |
SPARC |
secreted protein acidic and cysteine-rich |
TGF-α |
transforming growth factor alpha |
USP |
US pharmacopeia |